Category: PMCPA Case of the Week

Cases selected for the AskAnzal weekly PMCPA insight newsletter

8 Mar 2026

AUTH/3066/9/18: Head of Medicines Optimisation v GlaxoSmithKline

PMCPA case summary: Head of Medicines Optimisation complaint against GlaxoSmithKline. The provided case text contains no details of…

8 Mar 2026

AUTH/2242/6/09: Primary Care Pharmacist v Takeda β€” No breach (outwith scope of the Code)

Complaint alleged advertising of an unlicensed medicine. PMCPA recorded no breach because the matter was outwith the scope…

8 Mar 2026

Almirall website claims for Ilumetri: dosing and efficacy headlines ruled misleading (AUTH/3263/11/19)

PMCPA found Ilumetri website headline claims on dosing, efficacy and QoL misleading/unsupported (Clauses 7.2, 7.4) and ruled high…

8 Mar 2026

Ferring breached ABPI Code over Cortiment banner strapline implying broader ulcerative colitis use than licensed

A Cortiment rotating banner used the strapline β€œFor flaring mild to moderate UC patients”, which the Panel said…

8 Mar 2026

Sanofi breached ABPI Code over unsubstantiated β€œfewer prescriptions” claim for Toujeo DoubleStar in virtual promo meeting

Sanofi’s Toujeo DoubleStar slide deck wrongly claimed β€œfewer prescriptions”. PMCPA ruled the claim misleading and unsubstantiated, and found…

8 Mar 2026

Sanofi: uncertified advocacy planning templates treated as reps’ briefing material (Toujeo) (AUTH/3559/9/21)

Anonymous employee alleged Toujeo/Suliqua β€œadvocate” programme induced prescribing and misused HCP data. Panel found no inducement/GDPR breach, but…

8 Mar 2026

Novartis Entresto podcast: unsubstantiated β€˜energy’ claim, β€˜best’ implied superiority, and renal safety downplayed (AUTH/3635/4/22)

PMCPA found Novartis breached the ABPI Code over an Entresto nurse podcast: an unsubstantiated β€˜energy’ claim, β€˜best’ implying…

8 Mar 2026

AstraZeneca v GSK: Trelegy COPD NMA headline claim ruled misleading (AUTH/3699/10/22)

GSK’s HCP webpage/video used an NMA to headline β€œgreater exacerbation reduction” vs other COPD SITTs. PMCPA ruled the…

8 Mar 2026

AUTH/3823/9/23: GSK LinkedIn β€˜likes’ on US momelotinib approval posts – no breach (Clauses 12.1, 12.10, 26.1)

Complaint alleged GSK staff β€˜likes’ on LinkedIn posts about US FDA approval of momelotinib promoted a POM to…

8 Mar 2026

AUTH/3923/6/24: Complainant v GSK β€” Trelegy sales aid alleged off-label promotion (No breach)

Anonymous health professional alleged GSK sales aids promoted Trelegy for patients inadequately treated on multiple-inhaler triple therapy (MITT).…

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training